ECSP22010121A - Conjugados peptídicos de agentes dirigidos a microtúbulos como terapéuticos - Google Patents

Conjugados peptídicos de agentes dirigidos a microtúbulos como terapéuticos

Info

Publication number
ECSP22010121A
ECSP22010121A ECSENADI202210121A ECDI202210121A ECSP22010121A EC SP22010121 A ECSP22010121 A EC SP22010121A EC SENADI202210121 A ECSENADI202210121 A EC SENADI202210121A EC DI202210121 A ECDI202210121 A EC DI202210121A EC SP22010121 A ECSP22010121 A EC SP22010121A
Authority
EC
Ecuador
Prior art keywords
microtubule
therapeutics
targeting agents
peptide conjugates
conjugates
Prior art date
Application number
ECSENADI202210121A
Other languages
English (en)
Inventor
Daniel Richard Marshall
Robert John Maguire
Robert A Volkmann
Johanna Marie Csengery
Original Assignee
Cybrexa 3 Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cybrexa 3 Inc filed Critical Cybrexa 3 Inc
Publication of ECSP22010121A publication Critical patent/ECSP22010121A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a conjugados peptídicos de agentes dirigidos a microtúbulos tales como derivados de maitansinoide que son útiles para el tratamiento de enfermedades tal como cáncer.
ECSENADI202210121A 2019-07-10 2022-02-09 Conjugados peptídicos de agentes dirigidos a microtúbulos como terapéuticos ECSP22010121A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962872638P 2019-07-10 2019-07-10
US202063041324P 2020-06-19 2020-06-19

Publications (1)

Publication Number Publication Date
ECSP22010121A true ECSP22010121A (es) 2022-05-31

Family

ID=71944331

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202210121A ECSP22010121A (es) 2019-07-10 2022-02-09 Conjugados peptídicos de agentes dirigidos a microtúbulos como terapéuticos

Country Status (19)

Country Link
US (2) US11555019B2 (es)
EP (1) EP3996749A1 (es)
JP (1) JP7675060B2 (es)
KR (1) KR20220051332A (es)
CN (1) CN114302744B (es)
AU (1) AU2020311925A1 (es)
BR (1) BR112022000297A2 (es)
CA (1) CA3146385A1 (es)
CL (1) CL2022000043A1 (es)
CO (1) CO2022001315A2 (es)
CR (1) CR20220057A (es)
EC (1) ECSP22010121A (es)
IL (1) IL289659B1 (es)
MX (1) MX2022000450A (es)
MY (1) MY209459A (es)
PE (1) PE20220485A1 (es)
PH (1) PH12022550037A1 (es)
TW (1) TW202116356A (es)
WO (1) WO2021007402A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200121800A (ko) 2018-01-05 2020-10-26 싸이브렉사 1, 인크. 산성 또는 저산소성 질환에 걸린 조직에 관련된 질환의 치료를 위한 화합물, 조성물 및 방법
CA3146560A1 (en) 2019-07-10 2021-01-14 Cybrexa 2, Inc. Peptide conjugates of cytotoxins as therapeutics
MY209459A (en) 2019-07-10 2025-07-09 Cybrexa 3 Inc Peptide conjugates of microtubule-targeting agents as therapeutics
CN116940691A (zh) 2021-01-08 2023-10-24 赛博克萨2公司 用于制备缀合物连接部分的方法
PE20242180A1 (es) * 2021-11-17 2024-11-07 Cybrexa 4 Inc Conjugados peptidicos de inhibidores de tubulina peptidica como agentes terapeuticos

Family Cites Families (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5637770A (en) 1991-01-16 1997-06-10 Daiichi Pharmaceutical Co., Ltd. Hexa-cyclic compound
US6504029B1 (en) 1995-04-10 2003-01-07 Daiichi Pharmaceutical Co., Ltd. Condensed-hexacyclic compounds and a process therefor
KR100447539B1 (ko) 1995-08-02 2004-11-10 뉴캐슬 유니버시티 벤처스 리미티드 벤조이미다졸화합물과이를포함하는제약학적조성물및이화합물을이용한치료방법
PT897924E (pt) 1996-04-26 2002-03-28 Daiichi Seiyaku Co Processo para a preparacao de tetra-hidroindolizinas
TW527183B (en) 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
TW409058B (en) 1996-06-06 2000-10-21 Daiichi Seiyaku Co Method for preparation of a drug complex
IN189180B (es) 1997-07-09 2003-01-04 Chong Kun Dang Corp
MY132496A (en) 1998-05-11 2007-10-31 Vertex Pharma Inhibitors of p38
HK1040052B (zh) 1998-05-22 2006-09-15 第一制药株式会社 药物复合物
EP1619210A1 (en) 1998-10-30 2006-01-25 Daiichi Pharmaceutical Co., Ltd. DDS compounds and method for assaying the same
ES2234318T3 (es) 1998-11-03 2005-06-16 ABBOTT GMBH & CO. KG 2-fenil-benzimidazoles sustituidos, su preparacion y uso.
HRP20010573B1 (en) 1999-01-11 2006-04-30 Agouron Pharmaceuticals Tricyclic inhibitors of poly(adp-ribose) polymerases
DE19920936A1 (de) 1999-05-07 2000-11-09 Basf Ag Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung
ECSP003637A (es) 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas
US6699876B2 (en) 1999-11-18 2004-03-02 Les Laboratoires Servier Camptothecin analogue compounds
MXPA02005791A (es) 1999-12-13 2002-09-30 Lilly Co Eli Profarmacos de fosfato de pseudomicina.
EE200200522A (et) 2000-03-15 2004-04-15 Bristol-Myers Squibb Pharma Company Toimeainega konjugeerunud ensüüm-lõhustuv peptiid, seda sisaldav farmatseutiline kompositsioon ningühendi kasutamine kasvajavastase ravimina
BR0112417A (pt) 2000-07-13 2003-07-01 Daiichi Seiyaku Co Composições farmacêuticas contendo composto dds
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
US6441163B1 (en) * 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
MXPA04008419A (es) 2002-03-01 2004-11-26 Univ Tulane Conjugados de agentes terapeuticos o citotoxicos y peptidos biologicamente activos.
CA2479256A1 (en) 2002-03-20 2003-10-02 Bristol-Myers Squibb Company Phosphate prodrugs of fluorooxindoles
AU2003229953A1 (en) 2002-04-30 2003-11-17 Kudos Pharmaceuticals Limited Phthalazinone derivatives
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
CA2520997A1 (en) 2003-03-31 2004-10-14 Stacie Sara Canan-Koch Salts of tricyclic inhibitors of poly(adp-ribose) polymerases
JP4703566B2 (ja) 2003-05-14 2011-06-15 イムノゲン インコーポレーティッド 薬剤複合体組成物
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
CR20170291A (es) 2003-05-20 2017-07-27 Immunogen Inc Agentes citotoxicos mejorados que comprenden nuevos maitansinóides
ATE454893T1 (de) 2003-07-25 2010-01-15 Cancer Rec Tech Ltd Tricyclische parp-hemmer
GB0317466D0 (en) 2003-07-25 2003-08-27 Univ Sheffield Use
WO2005053662A1 (en) 2003-12-01 2005-06-16 Kudos Pharmaceuticals Limited Dna damage repair inhibitors for treatment of cancer
EP1718667B1 (en) 2004-02-23 2013-01-09 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
US8288557B2 (en) 2004-07-23 2012-10-16 Endocyte, Inc. Bivalent linkers and conjugates thereof
PL1794163T3 (pl) 2004-09-22 2010-06-30 Pfizer Sposób wytwarzania inhibitorów poli(adp-rybozo)polimerazy
JP2008513435A (ja) 2004-09-22 2008-05-01 ファイザー・インク ポリ（ａｄｐ−リボース）ポリメラーゼ阻害剤を含む治療用組成物
JP2008513436A (ja) 2004-09-22 2008-05-01 ファイザー・インク ８−フルオロ−２−｛４−［（メチルアミノ）メチル］フェニル｝−１，３，４，５−テトラヒドロ−６ｈ−アゼピノ［５，４，３−ｃｄ］インドール−６−オンのリン酸塩の多形性及び非晶質形態
CA2591148A1 (en) 2004-12-09 2006-06-15 Centocor, Inc. Anti-integrin immunoconjugates, methods and uses
AU2006206428B2 (en) 2005-01-18 2009-07-16 The Board Of Governors For Higher Education Selective delivery of molecules into cells or marking of cells in diseased tissue regions using environmentally senstive transmembrane peptide
US7301019B2 (en) 2005-01-21 2007-11-27 Immunogen, Inc. Method for the preparation of maytansinoid esters
ES2503719T3 (es) 2005-02-11 2014-10-07 Immunogen, Inc. Procedimiento para preparar conjugados de anticuerpos y de maitansinoides
US9707302B2 (en) 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
US20060233814A1 (en) 2005-04-15 2006-10-19 Immunogen Inc. Elimination of heterogeneous or mixed cell population in tumors
AU2006283726C1 (en) 2005-08-24 2015-05-07 Immunogen, Inc. Process for preparing maytansinoid antibody conjugates
WO2007041357A1 (en) 2005-09-29 2007-04-12 Abbott Laboratories 1h-benzimidazole-4-carboxamides substituted with phenyl at the 2-position are potent parp inhibitors
JP5117390B2 (ja) 2005-11-08 2013-01-16 イミュノジェン・インコーポレーテッド メイタンシノールの調製法
JP5289060B2 (ja) 2006-01-17 2013-09-11 アボット・ラボラトリーズ Ｐａｒｐインヒビターとの組合せ療法
BRPI0710407A2 (pt) 2006-05-04 2012-04-17 Genentech Inc poliptìdeos, peixes-zebra transgênicos, modelos de sistemas, métodos de identificação de compostos, de identificação de agentes, métodos de tratamento de disfunções relativas a apoptose, método de identificação de agentes de prevenção ou redução da apoptose, composição de aumento da apoptose, composições de redução ou prevenção de apoptose, composição de apoptose, método de detecção, kits e artigo industrializado
UY30639A1 (es) 2006-10-17 2008-05-31 Kudos Pharm Ltd Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
EP2805945B1 (en) 2007-01-10 2019-04-03 MSD Italia S.r.l. Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors
WO2008114114A2 (en) 2007-03-16 2008-09-25 Pfizer Products Inc. Poly(adp-ribose) polymerases inhibitor for treating ophthalmic condition
CN101784565B (zh) 2007-06-25 2014-12-10 恩多塞特公司 含有亲水性间隔区接头的共轭物
US8067613B2 (en) 2007-07-16 2011-11-29 Abbott Laboratories Benzimidazole poly(ADP ribose)polymerase inhibitors
PL2187965T3 (pl) 2007-08-17 2020-05-18 Purdue Research Foundation Koniugaty wiążący psma ligand-łącznik i sposoby ich zastosowania
CN102083461B (zh) 2008-04-30 2014-09-17 伊缪诺金公司 有效的偶联物和亲水性连接体
JP5579170B2 (ja) 2008-06-05 2014-08-27 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｄｇａｔ阻害剤とｐｐａｒ作動薬を含有する薬剤組み合わせ物
MX2011012794A (es) 2009-06-03 2012-05-08 Immunogen Inc Metodos de conjugacion.
US9353140B2 (en) 2009-11-25 2016-05-31 Academia Sinica BQC-G, a tumor-selective anti-cancer prodrug
RS55487B2 (sr) 2010-02-12 2024-06-28 Pfizer Soli i polimorfi 8-fluoro-2-{4-[(metilamino}metil]fenil}-1,3,4,5-tetrahidro-6h-azepino[5,4,3-cd]indol-6-ona
US20120322741A1 (en) 2010-02-25 2012-12-20 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
CL2011000718A1 (es) 2010-03-31 2012-04-09 Gilead Pharmasset Llc Proceso para la preparacion de compuestos fosforados enantiomericos.
JP5977229B2 (ja) 2010-05-05 2016-08-24 プロリンクス リミテッド ライアビリティ カンパニー 巨大分子共役体からの徐放
CA3032185C (en) 2010-07-13 2021-08-03 Council on Postsecondary Education, State of Rhode Island and Providence Plantations Environmentally sensitive composition comprising a ph triggered peptide and uses thereof
CA2808313C (en) 2010-08-13 2021-04-13 Rhode Island Board Of Governors For Higher Education Liposomes comprising ph low insertion peptide (phlip) polypeptides
CA2816681A1 (en) 2010-11-03 2012-05-10 Immunogen, Inc. Cytotoxic agents comprising new ansamitocin derivatives
WO2012135517A2 (en) 2011-03-29 2012-10-04 Immunogen, Inc. Preparation of maytansinoid antibody conjugates by a one-step process
ME03353B (me) 2011-03-29 2019-10-20 Immunogen Inc Priprema konjugata antitela i majtanzinoida jednostepenim postupkom
WO2013055987A1 (en) 2011-10-14 2013-04-18 Spirogen Sàrl Pyrrolobenzodiazepines and conjugates thereof
IL294622B2 (en) 2012-10-11 2023-10-01 Daiichi Sankyo Co Ltd Antibody-drug conjugates and methods for their preparation
US9872924B2 (en) 2012-10-19 2018-01-23 Daiichi Sankyo Company, Limited Antibody-drug conjugate produced by binding through linker having hydrophilic structure
WO2014066002A1 (en) 2012-10-23 2014-05-01 The Johns Hopkins University Novel self-assembling drug amphiphiles and methods for synthesis and use
WO2014093343A2 (en) 2012-12-10 2014-06-19 Massachusetts Institute Of Technology Multistage nanoparticle drug delivery system for the treatment of solid tumors
WO2014107024A1 (ko) 2013-01-03 2014-07-10 셀트리온 항체-링커-약물 결합체, 그의 제조방법 및 그를 포함하는 항암제 조성물
WO2014134483A2 (en) 2013-02-28 2014-09-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
TWI727919B (zh) 2013-12-19 2021-05-21 美商西雅圖遺傳學公司 與標的-藥物結合物併用之亞甲基胺基甲酸酯連接物
JP6663350B2 (ja) 2014-01-16 2020-03-11 クロヴィス・オンコロジー，インコーポレーテッド ヘテロ接合性の喪失を示す乳癌または卵巣癌の患者を治療するためのｐａｒｐ阻害剤の使用
DK3099717T3 (da) 2014-01-31 2019-07-01 Novartis Ag Antistofmolekyler med tim-3 og anvendelser deraf
JP2017114763A (ja) 2014-03-26 2017-06-29 第一三共株式会社 抗ｃｄ９８抗体−薬物コンジュゲート
SG11201608309PA (en) 2014-04-10 2016-11-29 Daiichi Sankyo Co Ltd Anti-her3 antibody-drug conjugate
US11185594B2 (en) 2014-04-10 2021-11-30 Daiichi Sankyo Company, Limited (Anti-HER2 antibody)-drug conjugate
US20170151339A1 (en) 2014-06-30 2017-06-01 Tarveda Therapeutics, Inc. Targeted conjugates and particles and formulations thereof
DK3182975T3 (da) 2014-08-22 2025-10-20 Pharma& Schweiz Gmbh Tabletter med høj doseringsstyrke af rucaparib
KR20170068409A (ko) 2014-09-16 2017-06-19 이즈 참 리미티드 항-egfr 항체 및 그의 용도
CA2961774C (en) 2014-10-07 2023-05-23 Immunomedics, Inc. Neoadjuvant use of antibody-drug conjugates
RU2711930C2 (ru) 2014-11-19 2020-01-23 Иммуноджен, Инк. Способ получения конъюгатов агента, связывающегося с клетками, и цитотоксического агента
JO3705B1 (ar) 2014-11-26 2021-01-31 Bayer Pharma AG إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
KR102407261B1 (ko) 2015-02-27 2022-07-06 서울대학교산학협력단 나노 항암제형 및 그 제조 방법
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
CN108473538B (zh) * 2015-10-28 2022-01-28 塔弗达治疗有限公司 Sstr靶向缀合物及其颗粒和制剂
AU2016359494B2 (en) 2015-11-24 2021-01-07 Theravance Biopharma R&D Ip, Llc Prodrugs of a JAK inhibitor compound for treatment of gastrointestinal inflammatory disease
KR102498258B1 (ko) 2016-01-20 2023-02-10 삼성디스플레이 주식회사 표시 장치
US20170267727A1 (en) * 2016-03-04 2017-09-21 Lehigh University Conjugates of pH Low Insertion Peptide and Monomethyl Auristatins in the Treatment of Solid Tumors
WO2017156191A1 (en) 2016-03-08 2017-09-14 Los Gatos Pharmaceuticals, Inc. Composite nanoparticles and uses thereof
WO2017180834A1 (en) * 2016-04-13 2017-10-19 Tarveda Therapeutics, Inc. Neurotensin receptor binding conjugates and formulations thereof
GB201608885D0 (en) 2016-05-20 2016-07-06 Univ Birmingham Treatment
US20190133980A1 (en) 2016-06-02 2019-05-09 Yale University Compositions and methods for targeting and treating homologous recombination-deficient tumors
WO2018023098A1 (en) * 2016-07-29 2018-02-01 Memorial Sloan Kettering Cancer Center Radiolabeled ligands for targeted pet/spect imaging and methods of their use
US10695396B2 (en) 2016-08-16 2020-06-30 National Institute Of Advanced Industrial Science And Technology Malignant tumor target peptide
CN117447553A (zh) * 2016-09-22 2024-01-26 罗德岛大学理事会 包含偶联至pH触发的多肽的荧光团的荧光化合物
PL3546448T3 (pl) 2016-11-25 2022-09-05 Mabwell (shanghai) Bioscience Co., Ltd. Łącznik stanowiący dipodstawiony amid kwasu maleinowego dla koniugacji przeciwciało-lek oraz sposób jego wytwarzania i zastosowanie
CN110312549B (zh) 2016-12-19 2021-06-29 莫尔豪斯医学院 用于通过抑制外泌体释放来治疗疾病的组合物和方法
EP3634498A4 (en) 2017-06-09 2021-08-25 Rhode Island Council on Postsecondary Education BOUND COMPOUNDS AND OTHER PH ACTIVATED COMPOUNDS
JP7248578B2 (ja) 2017-08-31 2023-03-29 第一三共株式会社 抗体－薬物コンジュゲートの新規製造方法
KR20200121800A (ko) 2018-01-05 2020-10-26 싸이브렉사 1, 인크. 산성 또는 저산소성 질환에 걸린 조직에 관련된 질환의 치료를 위한 화합물, 조성물 및 방법
MX2020007306A (es) 2018-01-12 2020-09-25 Prolynx Llc Tratamiento sinergico de cancer.
HUE067382T2 (hu) 2018-05-18 2024-10-28 Daiichi Sankyo Co Ltd Anti-MUC1-exatecan antitest-hatóanyag konjugátum
TW202519270A (zh) 2018-06-07 2025-05-16 美商思進公司 喜樹鹼結合物
CN109232719B (zh) 2018-09-21 2021-06-29 中国科学院理化技术研究所 一种pH响应的抗菌肽及其制备方法和应用
WO2020160009A1 (en) 2019-01-28 2020-08-06 Rhode Island Council On Postsecondary Education Phlip® targeted delivery of potent cytotoxic compounds
CN118221763A (zh) 2019-03-29 2024-06-21 免疫医疗有限公司 化合物及其缀合物
CA3146560A1 (en) 2019-07-10 2021-01-14 Cybrexa 2, Inc. Peptide conjugates of cytotoxins as therapeutics
MY209459A (en) 2019-07-10 2025-07-09 Cybrexa 3 Inc Peptide conjugates of microtubule-targeting agents as therapeutics
CN116940691A (zh) 2021-01-08 2023-10-24 赛博克萨2公司 用于制备缀合物连接部分的方法
CA3218253A1 (en) 2021-04-29 2022-11-03 Cybrexa 2, Inc. Dosing regimens of peptide conjugates of topoisomerase i inhibitors
PE20242180A1 (es) 2021-11-17 2024-11-07 Cybrexa 4 Inc Conjugados peptidicos de inhibidores de tubulina peptidica como agentes terapeuticos

Also Published As

Publication number Publication date
US11555019B2 (en) 2023-01-17
TW202116356A (zh) 2021-05-01
IL289659A (en) 2022-03-01
JP7675060B2 (ja) 2025-05-12
PH12022550037A1 (en) 2023-04-12
EP3996749A1 (en) 2022-05-18
IL289659B1 (en) 2026-01-01
MY209459A (en) 2025-07-09
CA3146385A1 (en) 2021-01-14
AU2020311925A1 (en) 2022-02-03
BR112022000297A2 (pt) 2022-03-15
US12234212B2 (en) 2025-02-25
US20240067616A1 (en) 2024-02-29
CN114302744A (zh) 2022-04-08
CL2022000043A1 (es) 2022-08-19
MX2022000450A (es) 2022-04-25
US20210009536A1 (en) 2021-01-14
CO2022001315A2 (es) 2022-05-10
CN114302744B (zh) 2025-08-26
KR20220051332A (ko) 2022-04-26
WO2021007402A1 (en) 2021-01-14
PE20220485A1 (es) 2022-04-04
JP2022541747A (ja) 2022-09-27
CR20220057A (es) 2022-07-19

Similar Documents

Publication Publication Date Title
ECSP22010228A (es) Conjugados peptídicos de citotoxinas como terapéuticos
ECSP22010121A (es) Conjugados peptídicos de agentes dirigidos a microtúbulos como terapéuticos
CY1125358T1 (el) Θεραπεια συνδυασμου η οποια περιλαμβανει εναν mdm2 αναστολεα και εναν ή περισσοτερους επιπροσθετους φαρμακευτικως δραστικους παραγοντες για την αντιμετωπιση καρκινων
CO2022000040A2 (es) Vesículas extracelulares microbianas procesadas
BR112018077492A2 (pt) métodos de tratamento de câncer de ovário
CO2017011216A2 (es) Compuestos heterocíclicos como inhibidores de lsd1.
MX2020001360A (es) Macrociclos de diarilo como moduladores de la proteina quinasa.
AR088694A1 (es) Peptidos citotoxicos y conjugados de anticuerpo-farmaco de los mismos
CO2022001083A2 (es) Conjugados de anticuerpos y fármacos anti-factor tisular y métodos relacionados
MX2018001723A (es) Conjugados farmaco-multiligando y usos de los mismos.
ECSP20061378A (es) COMPUESTOS DIÓLICOS DE AMINOPIRAZINA COMO INHIBIDORES DE PI3K-gamma
MX2017012102A (es) Agentes citotoxicos bifuncionales que contienen el farmacoforo de cti.
MX2022014277A (es) Metodos para una mejor administracion de agentes activos a tumores.
CO2020000227A2 (es) Moduladores de nlrp3
MX2020010408A (es) Conjugados de anticuerpo-farmaco y sus usos para el tratamiento del cancer.
MX2022014231A (es) Conjugados de anticuerpo-farmaco que se enfocan a la uparap.
CO2019002523A2 (es) Inhibidores de dopamina–β–hidroxilasa penetrantes de la barrera hematoencefálica
CO2024007413A2 (es) Conjugados peptídicos de inhibidores de tubulina peptídica como agentes terapéuticos
ECSP20082988A (es) Agonistas de tlr7
CL2018000726A1 (es) Tratamiento con conjugado syd985 de pacientes con cáncer resistente al tratamiento con t-dm1
BR112022022590A2 (pt) Formulações farmacêuticas de acetato de abiraterona e niraparibe
MX2019009909A (es) Composiciones farmaceuticas para terapia de combinacion.
AR120058A1 (es) Vesículas extracelulares microbianas procesadas
MX390150B (es) Obtencion de triterpenos del tipo lupano a partir de phoradendron vernicosum y su uso en el tratamiento de cancer.